Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16619843 | 0.87 | KMT2A (0.51) | NPC1RAB9APOLBKMT2AL3MBTL1 | |
| SCHEMBL4517538 | 0.86 | MAPK1 (0.53) | MAPK1NPC1RAB9APOLBKMT2A | |
| SCHEMBL31530616 | 0.83 | ALDH1A1 (0.49) | MAPK1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL30996674 | 0.83 | TSHR (0.42) | MAPK1POLBALDH1A1HCAR2ALPL | |
| SCHEMBL15467909 | 0.83 | HCAR2 (0.56) | HCAR2ALPL | |
| SCHEMBL16619632 | 0.82 | MAPK8 (0.46) | MAPK1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL17224847 | 0.81 | MAPK1 (0.51) | MAPK1NPC1RAB9APOLBKMT2A | |
| SCHEMBL5618892 | 0.77 | KMT2A (0.51) | MAPK1NPC1RAB9APOLBKMT2A | |
| SCHEMBL31130373 | 0.76 | NPC1 (0.49) | MAPK1NPC1RAB9APOLBKMT2A | |
| SCHEMBL28835655 | 0.76 | HCAR2 (0.66) | MAPK1NPC1RAB9APOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174886-B1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-02-17 | — | — | EP | disclosed |
| CN-106661043-B | 2-oxa-5-azabicyclo [2.2.1] hept-3-yl derivatives | 豪夫迈·罗氏有限公司 | 2020-01-17 | — | — | CN | disclosed |
| EP-3137459-B1 | MORPHOLIN-PYRIDINE DERIVATIVES HAVING AFFINITY TO THE TAAR1 RECEPTOR | HOFFMANN LA ROCHE (CH) | 2018-05-23 | — | — | EP | disclosed |
| US-9840501-B2 | Morpholin-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9790230-B2 | 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-3174886-A1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-06-07 | — | — | EP | disclosed |
| US-20170137435-A1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-05-18 | — | — | US | disclosed |
| EP-3137459-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-20170044145-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2016015333-A1 | 2-OXA-5-AZABICYCLO [2.2.1] HEPTAN-3-YL DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016016292-A1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-02-04 | — | — | WO | disclosed |
| WO-2015165835-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137435-A1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | HCRTR2, HCRTR1, CYP11B2 | MAPK1 2439/4885NPC1 524/4885RAB9A 2360/4885 |
| US-20170044145-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | OPRM1, MC2R, OPRL1 | MAPK1 913/4885NPC1 1204/4885RAB9A 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.